###### What is already known on this topic?

-   The debate about the pathogenicity of *Dientamoeba fragilis* is ongoing.

-   Previous studies tried to link the detection of the parasite in stool to the presence of gastrointestinal symptoms or observed whether successful eradication led to resolution of symptoms.

-   Faecal calprotectin is a sensitive marker of intestinal inflammation.

###### What this study adds?

-   We assessed whether the presence of *D. fragilis* in stool was associated with increased faecal calprotectin concentration.

-   The lack of association between *D. fragilis* colonisation and intestinal inflammation suggests that the parasite is a harmless commensal.

-   Routinely testing for *D. fragilis* in children with gastrointestinal symptoms should be discouraged.

Introduction {#s1}
============

*Dientamoeba fragilis*, a flagellate protozoan parasite that inhabits the human bowel, was first described 100 years ago by Jepps and Dobell, who thought of it as a non-pathogenic organism.[@R1] Since then, many studies have assessed the pathogenicity of *D. fragilis* in two indirect ways. First, by linking its presence to gastrointestinal symptoms, including diarrhoea and abdominal pain, and second, by observing whether eradication leads to resolution of symptoms. In [table 1](#T1){ref-type="table"}, we present an overview of the clinical studies that used these indirect methods from the year 2000 onwards. We show that, regardless of the method used, the controversy surrounding the pathogenicity of *D. fragilis* persists to this day.

###### 

Studies on the pathogenicity of *Dientamoeba fragilis*. Excluding case studies and studies published before the year 2000

  Study                                         Research question   Considers *Dientamoeba* to be   Detection method       
  --------------------------------------------- ------------------- ------------------------------- ------------------ --- -------------
  de Wit de *et al* [@R17]                      ✓                                                                      ✓   LM
  Bosman *et al* [@R18]                                             ✓                               ✓                      TFT
  Stark *et al* [@R19]                          ✓                                                   ✓                      PCR
  Vandenberg *et al* [@R20]                                         ✓                               ✓                      PCR and TFT
  Kurt *et al* [@R21]                                               ✓                               ✓                      LM
  Stark *et al* [@R22]                          ✓                   ✓                               ✓                      PCR
  Yakoob *et al* [@R23]                         ✓                                                   ✓                      PCR and LM
  Engsbro *et al* [@R24]                                            ✓                                                  ✓   PCR
  de Jong *et al* [@R12]                        ✓                   ✓                                                  ✓   PCR
  Röser *et al* [@R25]                                              ✓                                                  ✓   PCR
  Bruijnesteijn van Coppenraet *et al* [@R13]   ✓                                                                      ✓   PCR
  Krogsgaard *et al* [@R11]                     ✓                                                                      ✓   PCR and LM
  Ögren *et al* [@R26]                          ✓                                                   ✓                      PCR and LM
  Holtman *et al* [@R14]                        ✓                                                                      ✓   PCR
  Jokelainen *et al* [@R15]                     ✓                                                                      ✓   PCR

GI, gastrointestinal; LM, light microscopy; TFT, triple faeces test.

A direct method to assess the pathogenicity of *D. fragilis* was used in mice, where inoculation with *D. fragilis* induced an influx of eosinophils, neutrophils and macrophages in the intestinal wall.[@R2] If a similar inflammatory response would take place in the human gut, it should be possible to measure an increase of calprotectin in stool of colonised patients. Calprotectin is a peptide mainly released by neutrophils and also by macrophages and monocytes invading the gut mucosa during an inflammatory response.[@R3] To date, it has only been shown in a mouse model that *D. fragilis* is associated with an elevated faecal calprotectin concentration.[@R4] In humans, this has not yet been investigated. We aimed to study the relationship between *D. fragilis* colonisation and stool calprotectin measurements.

Methods {#s2}
=======

Design {#s2a}
------

This study was a retrospectively planned secondary analysis of prospectively collected data. We used stool samples from a community-based cohort of healthy children ('controls') aged 5--19 years[@R5] and from children with chronic abdominal pain and diarrhoea ('cases') aged 6--18 years.[@R6]

Setting and participants {#s2b}
------------------------

Controls (n=122) were recruited from primary and secondary schools in the Netherlands between June 2015 and March 2016. Participants defecated onto a stool collection sheet (FecesCatcher, TAG Hemi VOF, Zeijen, The Netherlands) held above their toilet and collected one stool sample in a screw top container. In this way, contamination by toilet water was impossible. Containers were sent to the hospital laboratory of the University Medical Center Groningen. All samples with a transport time exceeding 7 days were excluded, as stability of calprotectin was no longer guaranteed.[@R3] On arrival, samples were stored at −80°C until further analysis. Detailed inclusion and exclusion criteria are listed in the published study protocol.[@R5]

Cases had persistent diarrhoea for more than 4 weeks, or more than two episodes of abdominal pain and diarrhoea in the past 6 months, and consulted a paediatrician for the first time for this complaint. They were recruited from 3 tertiary care and 16 secondary care centres in both the Netherlands and Belgium.[@R6] Stool samples were collected between September 2014 and September 2016. The collection method, transport time and storage were similar as described for the controls. For the purpose of this study, we excluded stool samples from cases who were eventually diagnosed with a somatic gastrointestinal disorder or gastrointestinal infection other than *D. fragilis* and remained with 200 stool samples for the current study.

Measurements {#s2c}
------------

We used real-time PCR to determine the presence of *D. fragilis.* Additionally, faecal samples from cases were also tested for other gastrointestinal pathogens, including Shiga toxin-producing *Escherichia coli*, *E. coli O157gen*, *Cryptosporidium*, *Entamoeba histolytica*, *Giardia lamblia*, *Salmonella*, *Shigella/*enteroinvasive *E. coli* and *Campylobacter*.[@R7] Calprotectin concentrations were measured with the fCal ELISA test of BÜHLMANN Laboratories AG (Schönenbuch, Switzerland).

Variables {#s2d}
---------

Primary outcome of this study was the distribution of stool calprotectin concentrations in individuals colonised with *D. fragilis* compared with the distribution in those without the parasite.

Statistical methods {#s2e}
-------------------

Demographic information and stool results were recorded electronically using SPSS V.22.0 for Windows and are presented with GraphPad Prism V.7 for Mac (GraphPad Software, San Diego, California, USA). Standard descriptive statistics were used. Not normally distributed variables are presented as median and IQR and were tested using the Mann-Whitney U test. All tests were two sided, and the level of significance was set at a p value \<0.05.

Ethical approval {#s2f}
----------------

The data were collected and recorded by the investigators in such a manner that subjects could not be identified, neither directly nor through identifiers linked to the subjects. The legal guardians from all participants, as well as the children aged 12 years and above, gave informed consent to use residual materials for future research.

Results {#s3}
=======

We analysed stool samples from 122 controls (48% men) with a median (IQR) age of 12 (9--14) years, and from 200 cases (52% men) with a median (IQR) age of 12 (9--15) years. Gender and age distribution were not different between groups (p=0.491 and 0.154, respectively).

Prevalence {#s3a}
----------

[Figure 1](#F1){ref-type="fig"} shows that 87 of 122 controls (71%, 95% CI 63% to 79%) were colonised with *D. fragilis*, compared with 89 of 200 cases (45%, 95% CI 38% to 51%). The difference between groups was significant (p\<0.001).

![Point estimate (and 95% CI) of *Dientamoeba fragilis* prevalence in controls versus cases.](archdischild-2018-316383f01){#F1}

[Figure 2](#F2){ref-type="fig"} shows a decreasing prevalence of *D. fragilis* colonisation with increasing age during childhood and adolescence. When using 5 year intervals in age (5 to 9, 10 to 14, and 15 to 19 years), *D. fragilis* prevalence was respectively 67% (95%CI 57 to 76), 59% (95%CI 51 to 67) and 31% (95%CI 22 to 42).

![Point estimate (and 95% CI) of *Dientamoeba fragilis* prevalence per age category.](archdischild-2018-316383f02){#F2}

Faecal calprotectin {#s3b}
-------------------

Six of 322 frozen samples contained too little faecal material to measure the calprotectin concentration. The remaining 316 samples were further analysed. One hundred and seventy samples (54%, 95% CI 48% to 59%) tested positive for *D. fragilis.* The median (IQR) calprotectin concentration in these samples was 40 (40--55) µg/g, compared with 40 (40--75) μg/g in the *D. fragilis*-negative samples, as shown in [figure 3](#F3){ref-type="fig"}.

![Dot plot of faecal calprotectin concentrations in children with and without *Dientamoeba fragilis* colonisation. The top whisker indicates the 75th percentile.](archdischild-2018-316383f03){#F3}

Discussion {#s4}
==========

In this paper, we present for the first time that *D. fragilis* colonisation in children and teenagers is not associated with increased faecal calprotectin concentrations. In combination with the observation that *D. fragilis* colonisation is most prevalent in healthy individuals, we postulate that the parasite is a non-pathogenic organism. Presence of the parasite does not trigger inflammatory cells to release calprotectin.

Comparison with existing literature {#s4a}
-----------------------------------

As far as we know, no other faecal markers of intestinal inflammation have yet been investigated on their association with *D. fragilis*. We identified one animal study that investigated the relationship between the presence of *D. fragilis* and faecal calprotectin in mice.[@R4] The group of mice that were inoculated with *D. fragilis* had a mean (SD) faecal calprotectin concentration of 69 (22) ng/mL, compared with 33 (13) ng/mL in control mice. The small sample size (n=16) and the questionable applicability of this animal model to study human dientamoebiasis reduce the relevance of these observations.

Despite the use of the stool collection sheet to prevent the contamination of stool samples with toilet water, the prevalence of *D. fragilis* colonisation in the controls is among the highest currently reported. A literature search indicated that the prevalence of *D. fragilis* varied from 0.4% in healthy school children from Turkey[@R8] to 61% in healthy school children from Lebanon.[@R9] Higher prevalences can be partially ascribed to the use of real-time PCR, which is more sensitive than light microscopy.[@R7] Furthermore, higher rates of *D. fragilis* colonisation are often seen where sanitation and hygiene levels are poor.[@R10] Perhaps the high prevalence of *D. fragilis* colonisation is a reflection of the waning habit of hand washing before meals in the Netherlands.

The observation that *D. fragilis* is more commonly detected in healthy, non-symptomatic individuals than in symptomatic patients was previously done by numerous other adult and paediatric case--control studies.[@R11] All of these studies questioned the pathogenicity of *D. fragilis* (see [table 1](#T1){ref-type="table"}).

Implications for paediatric practice {#s4b}
------------------------------------

The availability of testing for *D. fragilis*, as part of the routine evaluation of children with gastrointestinal symptoms, varies between different European countries. We recently sent out a survey in the form of a clinical problem-solving exercise[@R16] to assess the current practice in the Netherlands and Belgium in relation to *D. fragilis.* The 30 respondents came from paediatric centres involved in the recruitment of cases for the current study. We observed that there was no uniformity in the detection of *D. fragilis* nor in the management of *D. fragilis* positive children with chronic abdominal pain and diarrhoea. The approach varied from ignoring the presence of the parasite to making an effort to eradicate.

The findings of the current study add to the ongoing debate about the pathogenicity of *D. fragilis.* Detection of the parasite in stool is not associated with increased faecal calprotectin concentrations, and we therefore postulate that the parasite is merely a harmless commensal.

We acknowledge that stool calprotectin testing is an indirect method to evaluate neutrophil invasion of the gut mucosa. However, our observations that *D. fragilis* colonisation is: (1) not associated with increased faecal calprotectin concentrations and (2) most prevalent in healthy individuals do not justify invasive procedures such as taking mucosal biopsies to further investigate its pathogenicity. We advise against testing for *D. fragilis* in children with chronic abdominal pain.
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